Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules

On Wednesday, Eli Lilly And Co (NYSE:LLY) has urged a federal appeals court to overturn a $183 million judgment stemming from accusations of defrauding Medicaid. The case, initiated in 2014, alleges that Eli Lilly underreported drug prices to Medicaid, resulting in smaller rebates owed to the program. Last week, Walgreens Boots Alliance Inc. (NASDAQ:WBA) agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act and state regulations. The U.S. pharma giant claims it is being wrongfully held liable despite adhering to its interpretation of Medicaid’s complex rebate requirements. The claims also highlight that Eli Lilly ...